Gold Coast biotech star rides global gold rally as ASX surges

Gold shone brightest in a bullish local session, surging 4.1 per cent to US$4,187 an ounce on Friday and delivering windfall momentum for Gold Coast portfolios already heavy with precious metals and healthcare stocks. The ASX 200 closed 0.92 per cent higher at 8,844, powered by local biotech leader Regenesis StemCell—a Main Beach-based regenerative medicine company—driving fresh wealth for SMSF-heavy investors across the region.

The rapid jump in gold drew immediate attention from retirees and financial advisers, particularly as yields from residential property continue to soften and auction clearance rates in Melbourne have slumped. For local investors, the double-digit advance in Regenesis StemCell this year has been a reminder that the Gold Coast’s best entrepreneurial bets are no longer found solely in high-rise apartments or holiday lets. Regenesis, which supplies next-gen cell therapies both locally and via export channels into Asia, has delivered consistent revenue growth since its last capital raising in early 2025. Private reports show the business now employs 25 Gold Coast scientists and clinical staff at its Parklands R&D hub.

Entrepreneurs such as Regenesis founder Dr Linh Ngo have taken full advantage of the shifting capital tide as higher global rates and volatile property values send more super fund flows into equities and alternatives. SMSF administrators across Southport and Burleigh confirm that allocations to gold, listed biotechs and even regulated crypto have grown notably since late 2025. Bitcoin’s 6.58 per cent leap to US$62,410 overnight was viewed by several local brokers as an opportunistic play, though gold remains top of mind for more risk-averse Gold Coast investors seeking a store of value as the AUD strengthens above US70c.

Business pivots and new money

While many mid-sized Gold Coast businesses remain tied to the cycles of property and tourism, Regenesis has quietly signalled a world beyond construction cranes and resort towers. Its recent partnership with a Victorian hospital network, focused on wound-healing therapies, is expected to underpin double-digit earnings growth into 2027 and could set a blueprint for local firms seeking to decouple from old-economy volatility. ASX-listed health and biotech shares broadly tracked the market rally, though Regenesis, as a private player, has seen its valuation soar through secondary equity sales to local family offices and superannuation trustees.

For now, investors with a Gold Coast postcode are watching a rare convergence—spot gold punching out record highs, tech and US equities strengthening sharply, and at least one local science success story beating the property blues. With WTI crude falling 2.78 per cent to US$68.78 and the Australian dollar ticking up to 0.6943, Australian portfolios have fresh choices and unfamiliar leaders. In this landscape, Regenesis and its peers may signal the future shape of self-funded retirement capital on the Coast—yielding not just from bricks and mortar but from petri dishes and clean-rooms on Southport’s research corridor.